Catalyst Pharmaceuticals Inc (CPRX)
21.68
-1.12
(-4.91%)
USD |
NASDAQ |
Nov 14, 16:00
21.69
+0.01
(+0.05%)
After-Hours: 17:42
Catalyst Pharmaceuticals Research and Development Expense (Quarterly): 3.284M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 3.284M |
| June 30, 2024 | 2.985M |
| March 31, 2024 | 2.581M |
| December 31, 2023 | 1.972M |
| September 30, 2023 | 83.66M |
| June 30, 2023 | 3.954M |
| March 31, 2023 | 3.562M |
| December 31, 2022 | 4.093M |
| September 30, 2022 | 8.31M |
| June 30, 2022 | 3.983M |
| March 31, 2022 | 3.403M |
| December 31, 2021 | 4.992M |
| September 30, 2021 | 4.487M |
| June 30, 2021 | 4.45M |
| March 31, 2021 | 3.007M |
| December 31, 2020 | 4.175M |
| September 30, 2020 | 3.749M |
| June 30, 2020 | 4.35M |
| March 31, 2020 | 4.223M |
| December 31, 2019 | 6.309M |
| September 30, 2019 | 4.597M |
| June 30, 2019 | 4.629M |
| March 31, 2019 | 3.308M |
| December 31, 2018 | 8.417M |
| September 30, 2018 | 4.538M |
| Date | Value |
|---|---|
| June 30, 2018 | 3.705M |
| March 31, 2018 | 3.259M |
| December 31, 2017 | 3.405M |
| September 30, 2017 | 2.705M |
| June 30, 2017 | 2.452M |
| March 31, 2017 | 2.814M |
| December 31, 2016 | 2.821M |
| September 30, 2016 | 2.494M |
| June 30, 2016 | 2.509M |
| March 31, 2016 | 3.546M |
| December 31, 2015 | 3.832M |
| September 30, 2015 | 3.043M |
| June 30, 2015 | 2.578M |
| March 31, 2015 | 2.350M |
| December 31, 2014 | 2.384M |
| September 30, 2014 | 2.886M |
| June 30, 2014 | 2.099M |
| March 31, 2014 | 2.749M |
| December 31, 2013 | 2.068M |
| September 30, 2013 | 2.804M |
| June 30, 2013 | 2.132M |
| March 31, 2013 | 1.092M |
| December 31, 2012 | 0.7447M |
| September 30, 2012 | 0.6548M |
| June 30, 2012 | 0.5327M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.972M
Minimum
Dec 2023
83.66M
Maximum
Sep 2023
8.076M
Average
4.038M
Median
Research and Development Expense (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 59.34M |
| Sarepta Therapeutics Inc | 224.48M |
| Alnylam Pharmaceuticals Inc | 270.93M |
| Biomarin Pharmaceutical Inc | 184.90M |
| Cytokinetics Inc | -- |